In blood cancers, however, STAT1, STAT3 and STAT5 play a dominant role and single STAT‐targeting therapies may suffice, also reflecting their less complex genetic driver mutation landscape. This evidence concerns the gene STAT5B and hematopoietic and lymphoid system neoplasm.